Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

262. The role of clopidogrel in the secondary prevention of recurrent ischemic vascular events after acute myocardial ischemia: a critical appraisal of the CURE trial.

The role of clopidogrel in the secondary prevention of recurrent ischemic vascular events after acute myocardial ischemia: a critical appraisal of the CURE trial. The role of clopidogrel in the secondary prevention of recurrent ischemic vascular events after acute myocardial ischemia: a critical appraisal of the CURE trial. The role of clopidogrel in the secondary prevention of recurrent ischemic vascular events after acute myocardial ischemia: a critical appraisal of the CURE trial. Boucher M (...) , Armstrong P, Pharand C, Skidmore B Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boucher M, Armstrong P, Pharand C, Skidmore B. The role of clopidogrel in the secondary prevention of recurrent ischemic vascular events after acute myocardial ischemia: a critical appraisal of the CURE trial. Ottawa: Canadian Coordinating Office for Health

2002 Health Technology Assessment (HTA) Database.

263. Do cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel?

Do cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel? Do cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel? Do cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel? Abdulwadud O Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Abdulwadud O. Do cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel? Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2002: 10 Authors' objectives This aim of this critical appraisal was to assess whether cardiac surgical patients on Clopidogrel bleed more and require more blood transfusions than those not on Clopidogrel. Project page URL Indexing Status Subject indexing

2002 Health Technology Assessment (HTA) Database.

264. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2002 NHS Economic Evaluation Database.

265. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. (PubMed)

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Despite the use of aspirin, there is still a risk of ischaemic events after percutaneous coronary intervention (PCI). We aimed to find out whether, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after PCI is superior to a strategy of no pretreatment and short-term therapy for only 4 weeks after PCI (...) .2658 patients with non-ST-elevation acute coronary syndrome undergoing PCI in the CURE study had been randomly assigned double-blind treatment with clopidogrel (n=1313) or placebo (n=1345). Patients were pretreated with aspirin and study drug for a median of 6 days before PCI during the initial hospital admission, and for a median of 10 days overall. After PCI, most patients (>80%) in both groups received open-label thienopyridine for about 4 weeks, after which study drug was restarted for a mean

2001 Lancet

266. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. (PubMed)

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients.We randomly assigned 12,562 patients who had presented within 24 hours after the onset of symptoms to receive clopidogrel (...) (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addition to aspirin for 3 to 12 months.The first primary outcome--a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke--occurred in 9.3 percent of the patients in the clopidogrel group and 11.4 percent of the patients in the placebo group (relative risk with clopidogrel as compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001

Full Text available with Trip Pro

2001 NEJM

267. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis

Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost (...) -effectiveness analysis Shah H, Gondek K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of antiplatelet therapy for the prevention of recurrent ischaemic stroke was studied. The antiplatelet agents considered were clopidogrel (75

2000 NHS Economic Evaluation Database.

268. Antiplatelet agents – clopidogrel (Plavix)

Antiplatelet agents – clopidogrel (Plavix) Antiplatelet agents – clopidogrel (Plavix) We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Antiplatelet agents – clopidogrel (Plavix) Share: Reading time approx. 2 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU Alert (...) This is a translation of version 1, published on October 29, 1999. The latest version of this report is not available in English. Clopidogrel is a recently approved drug which helps prevent the formation of blood clots in vascular diseases resulting from atherosclerosis. There is strong evidence that drugs which inhibit blood clots, eg, acetylsalicylic acid (ASA), have prophylactic effects in patients with atherosclerotic disease. The effects of clopidogrel have been compared to the effects of ASA in a randomized

2000 Swedish Council on Technology Assessement

269. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. (PubMed)

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced (...) by adenosine diphosphate.CAPRIE was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel (75 mg once daily) and aspirin (325 mg once daily) in reducing the risk of a composite outcome cluster of ischaemic stroke, myocardial infarction, or vascular death; their relative safety was also assessed. The population studied comprised subgroups of patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction

1996 Lancet